Davita Inc DVA

Thesis

DaVita operates roughly 2,600+ outpatient dialysis centers, treating end-stage renal disease (ESRD) patients three times a week, indefinitely, until transplant or death. Demand is non-discretionary: without dialysis, ESRD patients die within weeks. The US market is a structural duopoly with Fresenius (FMS); together they treat ~70% of US patients. Reimbursement is dominated by Medicare (~90% of patient volume), which is unprofitable on a unit basis, cross-subsidized by ~10-12% of patients on commercial insurance who pay 3-5x Medicare rates. This commercial-Medicare arbitrage is the entire economic engine.

The scorecard tells a clear story. Composite 81/100. ROIC 10y average is 13.4% on a deeply capital-light franchise (centers cost ~$2-3M to build and run for decades). FCF conversion 156% — DaVita prints more cash than GAAP earnings. Net debt/EBITDA is essentially zero at -0.24x (cash exceeds debt at the operating level after recent buyback-funded leverage moves; scorer notes flag net capital return phase). Share count is down ~9% over 10y, understating buyback intensity (the company has retired roughly half its shares since 2010). Interest coverage 4.8x. P/E TTM 14.1x vs 10y average 15.0x. EV/FCF 8.6x. Reverse-DCF implied growth is negative 2.5% — the market is pricing managed decline.

Base-case IV is $323, low $224, high $446 vs $151.65 price. Px/IV ratio 0.47. Even the LOW IV implies ~48% upside; base case implies ~113% upside. With Berkshire owning ~45% of shares outstanding and continuing to buy under $150 in the past, the alignment is real. Recommendation: Buy at current levels; add aggressively under $130.

Moat

DaVita's moat is real but narrowing — call it a NARROW moat with eroding cost-advantage characteristics.

1) Intangibles / Regulatory. Each dialysis center requires state Certificate of Need approvals in many jurisdictions, Medicare conditions-for-coverage certification, and a credentialed medical director. New entrants face 18-24 months of regulatory friction before treating a single patient. This is a Buffett-style "regulator buyer-of-choice" dynamic [1] — a long history of compliance and adequate capital deployment is itself a moat. DaVita's 30+ year operating history and integrated EHR (Falcon) are hard to replicate.

2) Switching Costs. Patients dialyze 3x/week for 3-4 hours. They build deep relationships with technicians and nurses; the chair becomes essentially a second home. Geographic switching is constrained by the need to be within ~20 minutes of a center. Once a patient is enrolled, churn is minimal (death and transplant are the dominant exit modes). Patient-level LTV is therefore largely a function of staying alive — DaVita has a structural interest in keeping patients alive and engaged with the system.

3) Cost Advantage / Scale. With ~2,600 centers and >200,000 patients, DaVita has scale economies in supplies (dialyzers, dialysate, EPO and other pharmaceuticals), labor (centralized nursing protocols), and real estate. Per Damodaran's framing of commodity-like industries [5], scale is the only durable cost advantage when the product is commoditized. Dialysis is a commodity service — the moat sits in the network density and the rate negotiations with commercial payers, not the procedure itself.

4) Network Effects (weak). Geographic density creates a soft network effect: more centers in a metro means better referral relationships with nephrologists, hospitals, and ESRD-detection programs. Nephrologists (the gatekeepers) prefer to send patients to centers where their other patients already go. This is real but won't show up in a moat scoring framework.

5) Brand / Demand-Side. Patients don't "choose" DaVita the way they choose Coca-Cola [3]. They go where their nephrologist sends them. There is no consumer brand equity. This matters because the moat is entirely supply-side and regulatory.

Erosion vectors. The moat narrows in three dimensions: (a) GLP-1s (Ozempic, Mounjaro, Wegovy) reduce diabetic and obese patient progression to ESRD over 10-20 years — the long-term TAM is structurally lower than the 4-5%/year trend that prevailed 2000-2020; (b) commercial insurer pushback via Marietta Memorial v. DaVita created risk that employer plans can carve out dialysis to push patients onto Medicare faster, shrinking the commercial cross-subsidy that funds profitability; (c) home dialysis and value-based-care shifts move some economics out of the captive in-center model. None of these kill the business — but they all compress the moat from "wide" to "narrow."

Failure mode parallel. The Buffett canon on commodity insurance [6] applies analogously: when the product is undifferentiated and price competition is fierce, only scale operators with disciplined underwriting (here, disciplined payer-mix and cost) earn returns. DaVita is the GEICO of dialysis — not because it has a Coke-like brand, but because it has the lowest cost per treatment in a heavily regulated, supply-constrained industry. Returns of 13.4% ROIC on a leveraged equity base have produced 25%+ ROE for two decades.

Moat verdict: NARROW.

Management & Capital Allocation

Javier Rodriguez has been CEO since June 2019; before that he ran the kidney care business for nearly a decade. He is a long-tenured operator, not a financier. The capital-allocation track record under his predecessor (Kent Thiry) and Rodriguez is one of the most aggressive buyback histories in the S&P 500 outside of AutoZone and a few other share-cannibals.

Buybacks. DaVita has retired more than 50% of its shares outstanding since 2010. The scorecard captures only the trailing 10y window (-9%), but the 15-year picture is staggering. Management has stated explicitly that buybacks are the default use of capital when intrinsic value exceeds market price. The math has worked: shares were repurchased in the $40s-$80s in 2014-2018 and the $70s-$110s in 2022-2023. At today's $151.65 vs base IV of $323, buybacks remain heavily accretive.

Debt. The company runs a leveraged balance sheet by design, recapitalizing periodically to fund repurchases. Interest coverage of 4.8x is adequate but not lavish; this is not a Buffett-style fortress balance sheet, it is a deliberate financial-engineering choice to amplify per-share owner earnings. Net debt/EBITDA prints negatively in the scorecard (-0.24x) which reflects timing and accounting; the underlying financial leverage is real and meaningful.

Acquisitions. The DMG (DaVita Medical Group) acquisition of HealthCare Partners in 2012 was a $4.4 billion strategic blunder — the company eventually divested DMG to Optum in 2019 at a substantial loss. Management has acknowledged the error and returned to the core dialysis franchise. Subsequent international expansion (Latin America, Asia) has been small-bolt-on and disciplined. Integrated Kidney Care (IKC), DaVita's value-based-care arm, has been a multi-year cash drag (~$200M+ losses) that management argues is a long-term option on capitated kidney care economics. The jury is still out; bears call it value destruction.

Compensation. Pay is heavily incentive-based with multi-year RSU/PSU grants tied to TSR and operating metrics. Insider ownership is modest in dollar terms but Buffett owns ~45% of the company through Berkshire, which acts as a structural governance backstop. DaVita has agreed to repurchase shares from Berkshire periodically to keep Berkshire's stake from drifting above ~45% — effectively a quasi-tender that returns capital to all shareholders proportionally. This is a Buffett-aligned mechanism that few companies have.

Past sins. DaVita has paid >$1B in DOJ settlements over the years for upcoding, anti-kickback issues with the American Kidney Fund, and labor-related allegations. These are real — but the business model survived all of them, and current compliance posture appears materially improved.

Buffett endorsement. Berkshire began accumulating in 2011 at ~$70 and has held through every controversy. Buffett rarely owns healthcare; the fact that DaVita has remained a top-15 Berkshire position for >12 years through three different lead managers (Combs/Weschler) is a strong external proof of capital allocation quality.

Capital allocator: B+. Heavy buybacks at attractive prices is the right strategy for this kind of business. The DMG misadventure costs them an A. Continued IKC losses keep them out of A-territory until that segment proves out.

Industry Structure

Threat of new entrants — LOW. Certificate of Need laws, Medicare certification, nephrologist relationships, real estate locations, and the need for ~$2-3M of capex and 18-24 months of ramp before profitability create high barriers. The duopoly with FMS is decades-old and regulators have explicitly blocked further consolidation (FTC blocked DaVita's attempt to acquire University of Utah dialysis assets). New entrants are limited to small regional operators (US Renal Care, Satellite) and hospital-affiliated programs that lack scale.

Bargaining power of suppliers — MODERATE. The big input cost is labor (nurses, techs, social workers), which has gotten meaningfully more expensive post-COVID — wage inflation 5-8% in 2021-2023 has compressed margins. Drug suppliers (Amgen for EPO/Mircera, Vifor for Velphoro) have had pricing power but the introduction of bundled payments capped reimbursement growth, transferring risk to the providers. Dialyzer/dialysate supply (Fresenius is itself a major supplier through its FMC division — a direct conflict for DVA) is concentrated.

Bargaining power of buyers — HIGH and rising. Medicare sets prices unilaterally — DaVita is a price-taker on ~90% of treatments. Commercial insurers (UnitedHealth, Anthem, Aetna) increasingly push for narrow networks and lower negotiated rates. The Marietta Memorial Supreme Court case (2022) was a partial loss for DaVita: the court allowed employer plans to apply uniform reductions on dialysis benefits, opening a path for self-funded employers to limit commercial dialysis exposure. Patients themselves have zero bargaining power.

Threat of substitutes — RISING (long-term). Kidney transplant remains the gold standard but supply-constrained (~25,000 transplants/year vs 550,000+ ESRD patients). Home hemodialysis and peritoneal dialysis are growing modalities that DaVita itself participates in but at lower margins per patient. The transformative substitute is GLP-1 / SGLT2-inhibitor adoption: drugs that materially slow CKD progression in diabetics will reduce the inflow of new ESRD patients over 10-20 years. DaVita estimates a single-digit-percent annual demand impact starting in the late 2020s; bears assume more.

Industry rivalry — LOW (duopoly). DVA and FMS act rationally — they don't price-compete on commercial rates because both benefit from a stable cross-subsidy. They compete on operational excellence, location density, and acquisition of independent centers. Margins have been remarkably stable at 14-16% operating margin for two decades. This is the defining feature of the business and the source of its returns.

Five Forces Verdict. Three positive forces (entry, rivalry, weak supplier power on most lines), two negative forces (rising buyer power, rising substitute threat). The good news (duopoly + entry barriers) is mostly priced into the historical record. The bad news (GLP-1, payer pushback, labor inflation) is largely what is suppressing the multiple today.

Industry Verdict: Good (was Excellent five years ago).

Inversion (Bear Case)

The strongest bear case for DVA is not GLP-1s alone, nor payer pushback alone, nor labor inflation alone — it is the compounding interaction of all three on a leveraged balance sheet, and the possibility that Berkshire's stake mark-to-market becomes a forced-seller ceiling rather than a floor. Let me build the bear case.

1) GLP-1 demand impairment is faster and deeper than DaVita admits. SELECT trial data shows GLP-1s reduce major adverse kidney events by ~24%; FLOW trial shows ~24% reduction in kidney disease progression for semaglutide in diabetic CKD. If GLP-1 penetration reaches 40-50% of diagnosed diabetics by 2030 (vs ~15% today) and another generation of oral GLP-1s (orforglipron) makes the drugs cheaper and more available, the inflow of new ESRD patients could turn negative as soon as 2028-2030. DaVita's volume base is ~200k+ US patients; if mortality (~20%/year exit rate) exceeds new admissions, the patient base shrinks 3-5%/year. Combined with stable per-patient revenue, that is mid-single-digit revenue decline. On a high-fixed-cost network, that is double-digit operating-income decline. The 13.4% ROIC compresses to single digits.

2) Commercial-Medicare arbitrage erodes. Marietta Memorial opened the door for self-insured employers to cap dialysis benefits or push patients to Medicare faster. The 30-month commercial-coordination period under Medicare Secondary Payer rules has been the cornerstone of the cross-subsidy. If Congress shortens this window (proposed but not enacted) or if employers structurally exit, the ~10-12% of patients on commercial paying 3-5x Medicare rates shrinks. Each percentage-point loss of commercial mix is roughly $200-300M of operating income. A 3-point shift would halve operating income.

3) Labor inflation is structural, not cyclical. Nephrology nursing is a small, specialized labor pool. Travel-nurse dynamics post-COVID raised the wage floor permanently. DaVita has guided to mid-single-digit annual wage growth indefinitely. With only 1-3% Medicare reimbursement updates, the wage-vs-rate gap compounds. Medicare's bundled rate has not kept up with inflation for years; the policy environment is hostile to upward revisions.

4) Leverage is no longer your friend in a declining business. The buyback-financed leverage that worked beautifully when owner earnings were stable becomes a millstone if owner earnings shrink. With 4.8x interest coverage and a model that depends on ongoing recapitalization, even a 20% EBITDA decline pushes coverage to 3.8x and may trigger covenant pressure or require buyback suspension. The Damodaran point on simulation [4]: base case looks fine, but the LEFT TAIL of the distribution gets ugly fast when fixed costs and fixed interest expenses meet declining volume.

5) Berkshire overhang. Berkshire owns ~45% of the float and has been a net buyer for 13 years. The day Buffett dies and Greg Abel/Todd Combs decide DVA is non-core for Berkshire 2.0 — given Abel's known preference for capital-light, growing businesses — the 45% stake becomes a multi-year overhang that caps the price even if fundamentals improve. The reverse buyback agreement that has historically protected the share price could be unwound. This is a tail risk specific to this name.

Failure analogues. Look at coal companies, US tobacco, US wireline telecom — businesses that traded at superficially cheap multiples on declining-but-still-cash-generative bases. Investors who bought at "8x EV/FCF" in 2010 in those industries lost money for a decade because the FCF kept declining and the multiple kept compressing. The Buffett canon on insurance commoditization [6] applies: when buyers don't differentiate and pricing is fierce, only the absolute lowest-cost operator earns returns — and even then, returns are mediocre. If DaVita is not the absolute lowest cost (FMS arguably is on supply integration), the bear case bites harder.

Quantification. Bear-case IV: assume owner earnings decline 3%/year for 10 years (vs scorecard's reverse-DCF implied -2.5%), then stabilize at ~70% of current levels. With 12% discount rate and 0% terminal growth, IV per share works out to ~$95-110 vs today's $151.65. That is ~30-40% downside. Add a Berkshire-overhang multiple compression and you can construct a $70-80 stock in a bad scenario, where it traded as recently as 2018 and 2022.

If I am right that the bear case unfolds, DVA could be worth $80-110 within 5-7 years, a 30-50% loss from today's price. That is the genuine downside, and any position must be sized for it.

Lollapalooza Bias Check

Multiple biases are pulling me toward a positive view that I should explicitly name and discount.

1) Authority bias — Buffett endorsement. Berkshire owning ~45% of DVA at an average cost well below today's price is the single most cited reason analysts (and I) feel comfortable. But Buffett has been wrong before (IBM, airlines round 1, Tesco), and the decision to own DVA was made by Ted Weschler, not Buffett himself. Weschler runs a $20B sleeve, not a $400B portfolio — a position that's high-conviction at his scale may not survive Berkshire 2.0. I am leaning on a halo effect.

2) Anchoring on intrinsic value. The scorecard says base IV is $323. The price is $151.65. The 47% px/IV ratio screams "buy." But the IV is computed from an owner-earnings number ($1.29B TTM) that may itself be peak-cycle. If GLP-1s compress steady-state owner earnings to $900M, base IV halves and the margin of safety vanishes. I should treat the IV range as a snapshot, not a steady state.

3) Recency / availability bias. GLP-1 stock-price drama (NVO, LLY) is fresh in my mind, but I do not have a calibrated view of the 10-year demand-impairment trajectory. I am pattern-matching on "market overreaction = opportunity" without doing the actual epidemiology.

4) Survivorship bias on cannibals. I am thinking AutoZone, NVR, IBM-circa-Buffett. I am not thinking Bed Bath & Beyond, GameStop, or coal companies — businesses that bought back shares aggressively into a declining base and destroyed equity value. The cannibal pattern works only if the underlying owner earnings are stable; it fails catastrophically if they decline.

5) Commitment / consistency. I came into this analysis primed by the scorecard's 81/100 composite and the prompt's framing as a "Berkshire holding." That predisposes me to a Buy. A flat read of the same numbers from a non-Buffett-context might feel more like a deep-value cigar butt than a compounder.

6) Social proof at Berkshire. If Buffett didn't own this, would I feel as comfortable owning a leveraged dialysis company facing GLP-1 risk and federal reimbursement risk? Probably not.

The lollapalooza here is positive — multiple biases pushing toward Buy. The discipline is to demand explicit numbers (specifically IV under bear-case owner earnings, not base) before sizing aggressively.

10-Year Outlook

Ten years from now, DaVita is likely smaller in patient count but larger in per-share owner earnings.

The central question is GLP-1 trajectory. The most probable scenario: GLP-1 penetration of diagnosed diabetics reaches 35-50% by 2035, slowing new ESRD admissions to 0-2% per year (vs 4-5% historically). Existing patient base attrits at ~20%/year (mortality + transplant), so the math is: new admissions roughly match attrition, and the patient base is flat-to-slightly-declining. Per-treatment revenue grows 1-2%/year (Medicare bundled rate updates). Wage costs grow 4-5%/year. Operating leverage works against the company: low-single-digit revenue growth on high fixed cost. Operating income flat to down low single digits.

Management will respond by: (a) closing under-utilized centers (estimated 5-10% of footprint over the decade); (b) accelerating buybacks at depressed multiples; (c) leaning into home dialysis where Medicare incentives are favorable; (d) potentially monetizing IKC if value-based care pays off, or shutting it down if not. Share count likely shrinks another 25-35% over the decade. International expansion (Latin America, Asia) provides a small offset.

Range of outcomes for per-share intrinsic value 10 years out, in nominal dollars: bear $130, base $280, bull $500. From today's $151.65, the IRRs are roughly: bear -1.5%/year, base 6.5%/year, bull 12.7%/year. With a ~50/35/15 probability weighting (slightly more bearish than the scorecard's IV midpoint to reflect GLP-1 uncertainty), expected IRR is ~6%/year — adequate but not stellar. The downside is bounded by Berkshire's continued ownership and management's buyback discipline. The upside requires GLP-1 impact to be milder than current consensus.

I can credibly model 10-year owner-earnings scenarios for this business because the demand drivers (diabetes, hypertension, aging) are well-documented and the regulatory framework (Medicare bundled payment) is stable and well-understood. The two big unknowns — GLP-1 penetration speed and commercial-Medicare arbitrage durability — are externally observable. This is a knowable business.

CONFIDENCE: medium